Products IgPro10
IgPro10 Approved Recruiting 🔥 Hot Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Feb 28, 2019 → Dec 20, 2029
About IgPro10 IgPro10 is a approved stage product being developed by CSL for Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT03684018. Target conditions include Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT03684018 Approved Recruiting Feb 28, 2019 Dec 20, 2029 Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT01390649 Approved Completed Nov 1, 2011 Sep 1, 2014 Immune Thrombocytopenic Purpura
Competing Products 20 competing products in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3